Included here is a list of publications from OCG programs. All published data are available to the research community through the program-specific data matrices.
* denotes publications from the CTD2 initiative that are results of intra-Network collaborations
CTD2 scientists at UCSF showed that tumor progression and dissemination are governed by evolutionary selection pressures that operate at a multicellular level and differ from the clonal events that drive initiation and the benign-malignant transition.
Integration of genome-scale RNAi and CRISPR-Cas9 screens across cancer cell lines with large protein-protein interaction networks revealed novel protein complexes.
Scientists established a panel of patient-derived xenografts (PDXs) from subtypes of T-cell lymphomas (TCL) and cell lines for target validation and drug testing. Stapled peptide ALRN-6924 which blocks interactions between p53, MDM2 and MDMX showed pre-clinical activity against TCL lines and PDXs.
TARGET study associated RNA signatures of cytotoxic tumor-infiltrating lymphocytes with the presence of activated NK-/T-cells and suggested improved outcomes in newly diagnosed high-risk neuroblastoma patients with MYCN-NA tumor.
Researchers performed an integrated analysis of TCGA genomic data and CPTAC proteomic data and demonstrated that A-to-I RNA editing contributes to proteomic diversity in breast cancer.
CTD2 scientists at Fred Hutchinson showed that the triplet combination of WEE1 tyrosine kinase inhibitor AZD1775, cisplatin, and docetaxel is safe and tolerable in a phase I clinical trial of head and neck cancer.